Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic Challenges of Tumor Tissue and Circulating Microsatellite Status Assessment in Metastatic Colorectal Cancer and Their Impact on Access to Immunotherapy: A Real-World Retrospective Study.

Cancers·2026
Same author

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Cancer cell·2026
Same author

Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts.

Oncology and therapy·2026
Same author

SparseXMIL: Leveraging sparse convolutions for context-aware and memory-efficient classification of whole slide images in digital pathology.

Medical image analysis·2026
Same author

Return to work among self-employed breast cancer survivors from the CANTO cohort.

Scientific reports·2026

Related Experiment Video

Updated: May 31, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

[Her2 a paradigm for targeted therapy].

Hélène Marijon1, Fabrice André

  • 1Hôpital Saint-Antoine, service d'oncologie médicale, Paris Cedex, France. helene.marijon@sat.aphp.fr

Bulletin Du Cancer
|June 21, 2011
PubMed
Summary

Her2-positive breast cancers are treated with trastuzumab, but resistance occurs. This review explores Her2 and trastuzumab mechanisms to overcome treatment resistance in breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Human Epidermal growth factor Receptor 2 (Her2) is overexpressed in 15% of breast cancers, impacting prognosis.
  • Targeted therapies like trastuzumab have improved outcomes for Her2-positive breast cancer patients.
  • Treatment resistance remains a significant clinical challenge, necessitating further research into Her2 pathways.

Purpose of the Study:

  • To review the mechanisms of action for Her2 and trastuzumab.
  • To elucidate pathways activated in tumors resistant to trastuzumab.
  • To identify strategies for overcoming treatment resistance in Her2-positive breast cancer.

Main Methods:

  • Literature review and synthesis of existing research on Her2 signaling.
  • Analysis of molecular mechanisms underlying trastuzumab efficacy and resistance.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Experiment Videos

Last Updated: May 31, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

  • Identification of potential therapeutic targets and strategies based on pathway analysis.

    • Main Results:

    • Her2 signaling pathways are complex and can be activated through various mechanisms.
    • Resistance to trastuzumab can arise from alterations in Her2 downstream signaling, bypass pathways, or tumor microenvironment factors.
    • Understanding these resistance mechanisms is crucial for developing effective combination therapies.

    Conclusions:

    • Trastuzumab is a vital therapy for Her2-positive breast cancer, but resistance limits its long-term efficacy.
    • Further investigation into resistance pathways is essential for improving patient outcomes.
    • Developing novel therapeutic strategies targeting resistance mechanisms holds promise for enhancing treatment effectiveness.